Damora Therapeutics, Inc.
DMRA
$31.04
$0.311.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -262.83M | -235.09M | -209.84M | -15.84M | -16.59M |
| Total Depreciation and Amortization | 96.00K | 94.00K | 34.00K | -27.00K | 23.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 193.61M | 187.64M | 184.72M | 2.76M | 3.35M |
| Change in Net Operating Assets | 24.61M | 22.47M | 18.36M | 879.00K | -46.00K |
| Cash from Operations | -44.52M | -24.89M | -6.73M | -12.23M | -13.26M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -17.37M | -17.37M | -17.37M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Investing | -17.37M | -17.37M | -17.37M | 0.00 | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 346.90M | 316.71M | 33.00K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 266.81M | 266.81M | 266.81M | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -21.44M | -20.75M | -- | -- | -- |
| Cash from Financing | 592.27M | 562.77M | 266.84M | -- | -- |
| Foreign Exchange rate Adjustments | -77.00K | 454.00K | 705.00K | 156.00K | 612.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 530.30M | 520.96M | 243.45M | -12.07M | -12.65M |